Shuonan Xu,Jianfei Zhu,Yawei Dou,Wei Tian,Yun Dai,Xianghui Luo,Hongtao Wang. Analysis of long-term outcomes and application of the tumor regression grading system in the therapeutic assessment of resectable limited-disease small cell lung cancer. Oncol Transl Med, 2016, 2: 227-233.
Analysis of long-term outcomes and application of the tumor regression grading system in the therapeutic assessment of resectable limited-disease small cell lung cancer
Received:March 24, 2016  Revised:August 10, 2016
View Full Text  View/Add Comment  Download reader
KeyWord:small cell lung cancer; tumor regression grading; neoadjuvant chemotherapy
Author NameAffiliationE-mail
Shuonan Xu Shaanxi Provincial People’s Hospital;Medical college of Yan'an University
The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University 
xsn101506@163.com 
Jianfei Zhu Shaanxi Provincial People’s Hospital;The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University zhujianfei718@163.com 
Yawei Dou Shaanxi Provincial People’s Hospital;The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University douzheng333@163.com 
Wei Tian Shaanxi Provincial People’s Hospital;The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University 939774621@qq.com 
Yun Dai Shaanxi Provincial People’s Hospital;The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University daiyun618@sina.com 
Xianghui Luo Shaanxi Provincial People’s Hospital;The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University luoxianghui700@sina.com 
Hongtao Wang Shaanxi Provincial People’s Hospital;The Third affiliated Hospital of the School of Medicine Xi'an JiaoTong University whtsyy139@qq.com 
Hits: 7410
Download times: 7742
Abstract:
      Objective The present study attempted to evaluate the value of neoadjuvant chemotherapy in limiteddisease small cell lung cancer (LD-SCLC), and to identify the predictive value of the tumor regression grading (TRG) system in LD-SCLC treatment-response and prognosis. Methods The records of patients with LD-SCLC (p-Stage I–IIIa) who underwent definitive radical resection at Shaanxi Provincial People’s Hospital between March 1, 2000 and March 31, 2014 were retrospectively analyzed. We compared the disease-free survival (DFS) and overall survival (OS) rates between Group A patients (patients who underwent surgery combined with pre- and post-operative chemotherapy) and Group B patients (patients who underwent surgery combined with adjuvant chemotherapy only) using the Kaplan-Meier method and the Mantel-Cox test. The specimens of patients who received neoadjuvant chemotherapy were reassessed according to the TRG system. Results The median DFS for 27 patients was 16.267 months and the median OS was 81.167 months (1- year OS, 74.07%; 3-year OS, 22.22%; 5-year OS, 14.81%). Thirteen patients received neoadjuvant chemotherapy, and their specimens were reassessed by TRG (pathological complete remission, 3/13, 23.08%). Patients in group A had a longer OS than those in group B (mean, 93.782 months versus 42.322 months, P = 0.025), although there was no significant difference in DFS between the two groups (median 20.100 months versus 14.667 months, P = 0.551). Statistical analysis revealed that TRG Grade (G) 0 (mean, 61.222 months) was associated with better OS than G1-2 (mean, 31.213 months) (P = 0.311). Conclusion Our study indicated that neoadjuvant chemotherapy combined with surgical resection may represent a feasible treatment method for patients with LD-SCLC. The TRG system may be a valuable prediction tool to assess neoadjuvant chemotherapeutic efficacy, especially in patients with G0 disease as determined by TRG; these patients may attain an improved survival benefit with neoadjuvant chemotherapy.
Close